Suggested remit: To appraise the clinical and cost effectiveness of tislelizumab within its marketing authorisation for treating unresectable, locally advanced or metastatic oesophageal squamous cell cancer that has not been previously treated.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 5113

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 5113 19 March 2025 - 16 April 2025

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
19 March 2025 In progress. Scoping commencing
04 June 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-May 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
01 December 2023 Please note that following on from advice received from the company, further information regarding the timelines for this appraisal will be available in due course. In the meantime, NICE will continue to monitor the situation and will provide an update as and when the situation changes.
04 May 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
14 April 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
14 April 2022 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual